Cargando…
Aldosterone breakthrough does not alter central hemodynamics
INTRODUCTION: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are widely used in congestive heart failure and chronic kidney disease, but up to 40% of patients will experience aldosterone breakthrough, with aldosterone levels rising above pre-treatment levels after 6–12 mo...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843861/ https://www.ncbi.nlm.nih.gov/pubmed/28992758 http://dx.doi.org/10.1177/1470320317735002 |